Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Sarfez Pharmaceuticals
Sarfez Pharmaceuticals
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Soaanz
Torsemide
2021-06-14
2033
Heart failure
,
Hypertension
,
Chronic kidney failure
,
Liver cirrhosis
,
Nephrotic syndrome
,
Edema
,
Ascites
,
Pulmonary edema
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Torsemide
food-drug interactions
,
body weight changes
,
overactive urinary bladder
,
urinary incontinence
,
healthy volunteers/patients
,
hypertension
,
heart failure
,
chronic renal insufficiency
,
edema
,
iron overload
,
hypernatremia
Aspartame
neoplasms
,
melanoma
,
overweight
,
weight loss
,
nutrition disorders
,
hemophilia b
,
sickle cell anemia
,
thalassemia
,
type 2 diabetes mellitus
,
diabetes mellitus
,
obesity
,
type 1 diabetes mellitus
,
transient ischemic attack
,
hypoxia
,
diabetic neuropathies
,
nephritis
,
knee osteoarthritis
,
osteoarthritis
,
diastolic heart failure
,
myocardial reperfusion
,
pituitary dwarfism
,
insulin resistance
,
cardiovascular diseases
,
endocrine system diseases
,
laron syndrome
,
growth disorders
,
latent autoimmune diabetes in adults
,
hemophilia a
,
dwarfism
,
dyslipidemias
,
heart failure
,
chronic renal insufficiency
,
kidney diseases
,
heart disease risk factors
,
inflammation
,
atherosclerosis
Spirolactone
heart failure
,
chronic renal insufficiency
,
kidney diseases
Histone-arginine methyltransferase carm1
healthy volunteers/patients
,
small cell lung carcinoma
,
obesity
,
overweight
,
psoriasis
,
urologic neoplasms
,
carcinoma
,
non-small-cell lung carcinoma
,
head and neck neoplasms
,
brain neoplasms
,
breast neoplasms
,
lung neoplasms
,
systemic lupus erythematosus
,
type 2 diabetes mellitus
,
diabetes mellitus
,
covid-19
,
kidney diseases
,
polycystic kidney diseases
,
asthma
Surlorian
hepatitis b
,
chronic hepatitis b
,
hepatitis
,
hepatitis a
,
virus diseases
,
herpesviridae infections
,
adenocarcinoma of lung
,
hepatitis c
,
ebola hemorrhagic fever
,
atopic dermatitis
,
eczema
,
dermatitis
,
cardiovascular diseases
,
coronary artery disease
,
respiratory tract diseases
,
major depressive disorder
,
pulmonary tuberculosis
,
multidrug-resistant tuberculosis
,
psoriatic arthritis
,
venous thromboembolism
,
human influenza
,
thromboembolism
,
venous thrombosis
,
pulmonary embolism
,
prostatic neoplasms
,
leukemia
,
myeloid leukemia acute
,
myeloid leukemia
,
thrombosis
,
prostatectomy
,
neonatal alloimmune thrombocytopenia
,
myasthenia gravis
,
psoriasis
,
lupus nephritis
,
nephritis
Isoxaflutole
healthy volunteers/patients
,
non-small-cell lung carcinoma
,
type 2 diabetes mellitus
,
covid-19
,
virus diseases
,
sickle cell anemia
,
erectile dysfunction
,
systemic lupus erythematosus
,
psoriatic arthritis
,
arthritis
,
prostatic neoplasms
,
breast neoplasms
,
ovarian neoplasms
,
pancreatic neoplasms
,
esophageal neoplasms
,
lung neoplasms
,
urinary bladder neoplasms
,
uterine neoplasms
,
liver neoplasms
,
kidney neoplasms
,
uterine cervical neoplasms
,
colonic neoplasms
,
hematologic diseases
,
hematopoietic stem cell transplantation
,
bone marrow transplantation
,
acromegaly
,
cardiovascular diseases
,
neoplasms
,
rare diseases
,
treatment adherence and compliance
,
oncogenes
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use